SBS is a rare and disablingcondition. The standard management is based on diet optimization withparenteral supplementation. In addition, glucagon-like peptide-2 (GLP-2)analogs, have shown promising results as disease-modifying therapies for SBS. Short bowel syndrome (SBS) isdefined as a reduction in functional intestinal length to less than 200 cm,leading to intestinal failure (IF) leading to malnutrition and parenteralsupport dependency. This review discusses the current management of SBS-CIFpatients, the place of GLP-2 analog treatment in terms of efficacy, safety andavailability, and the new perspectives opened by the use of enterohormones. Clinical trials and real-world experience demonstrated that Teduglutide reduces dependence on parenteral support andhas a place in the management of patients with SBS-CIF. The use of Teduglutide should be discussed inpatients stabilized after resection and its introduction requires the advice ofan expert center capable of assessing the benefit-risk ratio. The complex, individualized management of SBS-C IF requires theexpertise of a specialized IF center which a multidisciplinary approach. Thearrival of new treatments will call for new therapeutic strategies, and thequestion of how to introduce and monitor them will represent a new therapeuticchallenge.